肌层浸润性膀胱癌共识分子分型
该研究基于16个已发表数据集和两个额外队列的1750例MIBC转录组谱,对6个独立分型系统进行网络分析,达成国际共识的6个分子亚类,并提供单样本分类器,但受限于回顾性数据收集和治疗信息不完整。
要点
- 共识确定了6个MIBC分子亚类:luminal papillary、luminal nonspecified、luminal unstable、stroma-rich、basal/squamous和neuroendocrine-like。
- 各共识亚类在致癌机制、免疫与基质细胞浸润、组织学与临床特征及预后方面存在差异。
- 提供单样本分类器,可将肿瘤样本转录组分配至共识亚类,便于临床应用。
核心结论
- 该国际共识系统为MIBC分子分型提供了稳健框架,有助于未来前瞻性临床试验中预测性生物标志物的测试与验证。
研究设计与样本
- 研究使用来自16个已发表数据集和两个额外队列的1750例MIBC转录组谱,对六个独立MIBC分类系统进行网络分析。
主要发现
- 共识确定了六个分子亚类:luminal papillary(24%)、luminal nonspecified(8%)、luminal unstable(15%)、stroma-rich(15%)、basal/squamous(35%)和neuroendocrine-like(3%)。
- 共识亚类在致癌机制、免疫与基质细胞浸润、组织学与临床特征(包括结局)方面存在差异。
- 提供了单样本分类器,可将肿瘤样本转录组分配至共识亚类标签。
关键数值与推荐
- 共识亚类比例:luminal papillary 24%、luminal nonspecified 8%、luminal unstable 15%、stroma-rich 15%、basal/squamous 35%、neuroendocrine-like 3%。
临床怎么用
- 单样本分类器可用于将MIBC肿瘤样本转录组分配至共识分子亚类,辅助预后分层和未来治疗反应研究。
局限性
- 局限性包括回顾性临床数据收集和缺乏患者治疗的完整信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Muscle-invasive bladder cancer (MIBC) is a molecularly diverse disease with heterogeneous clinical outcomes. Several molecular classifications have been proposed, but the diversity of their subtype sets impedes their clinical application. OBJECTIVE: To achieve an international consensus on MIBC molecular subtypes that reconciles the published classification schemes. DESIGN, SETTING, AND PARTICIPANTS: We used 1750 MIBC transcriptomic profiles from 16 published datasets and two additional cohorts. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We performed a network-based analysis of six independent MIBC classification systems to identify a consensus set of molecular classes. Association with survival was assessed using multivariable Cox models. RESULTS AND LIMITATIONS: We report the results of an international effort to reach a consensus on MIBC molecular subtypes. We identified a consensus set of six molecular classes: luminal papillary (24%), luminal nonspecified (8%), luminal unstable (15%), stroma-rich (15%), basal/squamous (35%), and neuroendocrine-like (3%). These consensus classes differ regarding underlying oncogenic mechanisms, infiltration by immune and stromal cells, and histological and clinical characteristics, including outcomes. We provide a single-sample classifier that assigns a consensus class label to a tumor sample's transcriptome. Limitations of the work are retrospective clinical data collection and a lack of complete information regarding patient treatment. CONCLUSIONS: This consensus system offers a robust framework that will enable testing and validation of predictive biomarkers in future prospective clinical trials. PATIENT SUMMARY: Bladder cancers are heterogeneous at the molecular level, and scientists have proposed several classifications into sets of molecular classes. While these classifications may be useful to stratify patients for prognosis or response to treatment, a consensus classification would facilitate the clinical use of molecular classes. Conducted by multidisciplinary expert teams in the field, this study proposes such a consensus and provides a tool for applying the consensus classification in the clinical setting.
引用
- Kamoun A, de Reyniès A, Allory Y, et al. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur Urol. 2019. PMID: 31563503. doi:10.1016/j.eururo.2019.09.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。